FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4239602124> ?p ?o ?g. }

• W4239602124 endingPage "2806" @default.
• W4239602124 startingPage "2798" @default.
• W4239602124 abstract "Lineage-specific growth factors mobilize peripheral blood progenitor cells (PBPC) and accelerate hematopoietic recovery after high-dose chemotherapy. Recombinant human thrombopoietin (rhTPO) may further increase the progenitor-cell content and regenerating potential of PBPC products. We evaluated the safety and activity of rhTPO as a PBPC mobilizer in combination with granulocyte colony-stimulating factor (G-CSF) in 29 breast cancer patients treated with high-dose chemotherapy followed by PBPC reinfusion. Initially, patients received escalating single doses of rhTPO intravenously (IV) at 0.6, 1.2, or 2.4 μg/kg, on day 1. Subsequent patients received rhTPO 0.6 or 0.3 μg/kg on days −3, −1, and 1, or 0.6 μg/kg on days −1 and 1. G-CSF, 5 μg/kg IV or subcutaneously (SC) twice daily, was started on day 3 and continued through aphereses. Twenty comparable, concurrently and identically treated patients (who were eligible and would have been treated on protocol but for the lack of study opening) mobilized with G-CSF alone served as comparisons. CD34+ cell yields were substantially higher with the first apheresis following rhTPO and G-CSF versus G-CSF alone: 4.1 × 106/kg (range, 1.3 to 17.6) versus 0.8 × 106/ kg (range, 0.3 to 4.2), P = .0003. The targeted minimum yield of 3 × 106CD34+ cells/kg was procured following a single apheresis procedure in 61% of the rhTPO and G-CSF–mobilized group versus 10% of G-CSF–mobilized patients (P = .001). In rhTPO and G-CSF mobilized patients, granulocyte (day 8 v 9, P= .0001) and platelet recovery (day 9 v 10, P= .07) were accelerated, and fewer erythrocyte (3 v 4,P = .02) and platelet (4 v 5, P = .02) transfusions were needed compared with G-CSF–mobilized patients. Peripheral blood platelet counts, following rhTPO and G-CSF, were increased by greater than 100% and the platelet content of PBPC products by 60% to 110% on the first and second days of aphereses (P < .0001) with the greatest effect seen with repeated dosing of rhTPO at 0.6 μg/kg. rhTPO is safe and well tolerated as a mobilizing agent before PBPC collection. Mobilization with rhTPO and G-CSF, in comparison to a comparable, nonrandomized G-CSF–mobilized group of patients, decreases the number of apheresis procedures required, may accelerate hematopoietic recovery, and may reduce the number of transfusions required following high-dose chemotherapy for breast cancer." @default.
• W4239602124 created "2022-05-12" @default.
• W4239602124 creator A5009104622 @default.
• W4239602124 creator A5011178245 @default.
• W4239602124 creator A5018527792 @default.
• W4239602124 creator A5023727765 @default.
• W4239602124 creator A5023917993 @default.
• W4239602124 creator A5027495771 @default.
• W4239602124 creator A5030323121 @default.
• W4239602124 creator A5030731004 @default.
• W4239602124 creator A5039374832 @default.
• W4239602124 creator A5041200743 @default.
• W4239602124 creator A5047005057 @default.
• W4239602124 creator A5047228203 @default.
• W4239602124 creator A5055229834 @default.
• W4239602124 creator A5057047127 @default.
• W4239602124 creator A5059734562 @default.
• W4239602124 creator A5061672328 @default.
• W4239602124 creator A5064172508 @default.
• W4239602124 creator A5064298563 @default.
• W4239602124 creator A5072467743 @default.
• W4239602124 creator A5073784584 @default.
• W4239602124 creator A5084347950 @default.
• W4239602124 date "1999-05-01" @default.
• W4239602124 modified "2023-10-18" @default.
• W4239602124 title "Recombinant Human Thrombopoietin in Combination With Granulocyte Colony-Stimulating Factor Enhances Mobilization of Peripheral Blood Progenitor Cells, Increases Peripheral Blood Platelet Concentration, and Accelerates Hematopoietic Recovery Following High-Dose Chemotherapy" @default.
• W4239602124 cites W1129691885 @default.
• W4239602124 cites W144754814 @default.
• W4239602124 cites W160332237 @default.
• W4239602124 cites W1757326868 @default.
• W4239602124 cites W1872096120 @default.
• W4239602124 cites W1929549982 @default.
• W4239602124 cites W1965375035 @default.
• W4239602124 cites W1983612778 @default.
• W4239602124 cites W2038818733 @default.
• W4239602124 cites W2093758335 @default.
• W4239602124 cites W2103818290 @default.
• W4239602124 cites W2120093724 @default.
• W4239602124 cites W2121960093 @default.
• W4239602124 cites W2125887123 @default.
• W4239602124 cites W2143531841 @default.
• W4239602124 cites W2162839120 @default.
• W4239602124 cites W2230842386 @default.
• W4239602124 cites W2262312629 @default.
• W4239602124 cites W2276767966 @default.
• W4239602124 cites W2288636678 @default.
• W4239602124 cites W2300796896 @default.
• W4239602124 cites W2312239978 @default.
• W4239602124 cites W2317912629 @default.
• W4239602124 cites W2340074707 @default.
• W4239602124 cites W2403174101 @default.
• W4239602124 cites W2409697824 @default.
• W4239602124 cites W268307997 @default.
• W4239602124 cites W34270861 @default.
• W4239602124 cites W4250903776 @default.
• W4239602124 cites W92133935 @default.
• W4239602124 doi "https://doi.org/10.1182/blood.v93.9.2798.409k26_2798_2806" @default.
• W4239602124 hasPublicationYear "1999" @default.
• W4239602124 type Work @default.
• W4239602124 citedByCount "7" @default.
• W4239602124 crossrefType "journal-article" @default.
• W4239602124 hasAuthorship W4239602124A5009104622 @default.
• W4239602124 hasAuthorship W4239602124A5011178245 @default.
• W4239602124 hasAuthorship W4239602124A5018527792 @default.
• W4239602124 hasAuthorship W4239602124A5023727765 @default.
• W4239602124 hasAuthorship W4239602124A5023917993 @default.
• W4239602124 hasAuthorship W4239602124A5027495771 @default.
• W4239602124 hasAuthorship W4239602124A5030323121 @default.
• W4239602124 hasAuthorship W4239602124A5030731004 @default.
• W4239602124 hasAuthorship W4239602124A5039374832 @default.
• W4239602124 hasAuthorship W4239602124A5041200743 @default.
• W4239602124 hasAuthorship W4239602124A5047005057 @default.
• W4239602124 hasAuthorship W4239602124A5047228203 @default.
• W4239602124 hasAuthorship W4239602124A5055229834 @default.
• W4239602124 hasAuthorship W4239602124A5057047127 @default.
• W4239602124 hasAuthorship W4239602124A5059734562 @default.
• W4239602124 hasAuthorship W4239602124A5061672328 @default.
• W4239602124 hasAuthorship W4239602124A5064172508 @default.
• W4239602124 hasAuthorship W4239602124A5064298563 @default.
• W4239602124 hasAuthorship W4239602124A5072467743 @default.
• W4239602124 hasAuthorship W4239602124A5073784584 @default.
• W4239602124 hasAuthorship W4239602124A5084347950 @default.
• W4239602124 hasConcept C10205521 @default.
• W4239602124 hasConcept C109159458 @default.
• W4239602124 hasConcept C126322002 @default.
• W4239602124 hasConcept C126894567 @default.
• W4239602124 hasConcept C201750760 @default.
• W4239602124 hasConcept C203014093 @default.
• W4239602124 hasConcept C2776689292 @default.
• W4239602124 hasConcept C2776694085 @default.
• W4239602124 hasConcept C2776738589 @default.
• W4239602124 hasConcept C2777767877 @default.
• W4239602124 hasConcept C2777863708 @default.
• W4239602124 hasConcept C28328180 @default.
• W4239602124 hasConcept C54355233 @default.
• W4239602124 hasConcept C71924100 @default.
• W4239602124 hasConcept C86803240 @default.
• W4239602124 hasConcept C89560881 @default.

• next